11 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology”
This letter discusses the use of serial trichoscopy versus a modified hair pull test for monitoring localized alopecia areata but reports no new clinical results.
This review examines the effects of sex hormones on hair growth and the pathogenesis of related hair disorders, highlighting current management benefits and controversies but reporting no new results.
37 citations
,
May 2016 in “Deutsches Arzteblatt International”
This review outlines various causes and manifestations of hair loss, highlighting that each type has distinct underlying mechanisms and requires specific treatment approaches, without reporting new clinical results.
Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.
Alcohol consumption can trigger hair shedding and affect hairtreatment effectiveness, especially in those with autoimmune diseases. Treatments mentioned include RU58841, oral minoxidil, and stemoxydine, with finasteride also noted by another user.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.